Abbott closes Kos acquisition
Executive Summary
Abbott completes its $3.7 billion cash purchase of Kos Pharmaceuticals in just thirty business days, CFO Thomas Freyman announces during the JP Morgan Healthcare Conference Jan. 9. The deal, proposed by Abbott in early November, will help diversify the firm's existing cardiovascular franchise, and could also expand its pipeline into respiratory diseases (1"The Pink Sheet" Nov. 13, 2006, p. 13)...